Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing concentrated safety monitoring of ShuXueNing injection
ChiCTR-OPC-15006649Phase 4Not yet recruiting
- Sponsor
- Tianjin University of Traditional Chinese Medicine
- Start
- Aug 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of shuxuening in adverse drug reaction (ADR), sponsored by Tianjin University of Traditional Chinese Medicine. Primary endpoint: Adverse drug reactions. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
shuxuening
03
Conditions
adverse drug reaction (ADR)
Beyond the preview
Go deeper on ChiCTR-OPC-15006649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006649.